Use of test
Gene fusions involving the IGH gene at 14q32 and the MAF gene at 16q23 are seen in multiple myeloma. The identification of such fusions can assist in the diagnosis and classification of this disease.
Presence of an IGH-MAF rearrangement is a sign of poor prognosis in myeloma.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis using probes to identify fusion of the IGH with MAF gene due to a t(14;16)(q32;q23) translocation.
Requesting the test
This test is usually requested by a haematologist or oncologist. It is usually requested as part of the Myeloma panel
0.5 mL bone marrow in transport media.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
2 business days.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.
Click here for our billing policy.